Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs. In this study, 36 patients who initially responded to this treatment were evaluated to determine whether clinical relapse was associated with escape from endocrine suppression. Plasma estrone levels rose significantly (mean increase, 6.8 pg/ml) during the final 15% of time on treatment before relapse. Mean plasma estradiol, dehydroepiandrosterone sulfate, and androstenedione levels also rose with the approach of the relapse, but the increases were not statistically significant. The increase in estrone may contribute to the progression of disease.

Original publication

DOI

10.1210/jcem-58-1-99

Type

Journal article

Journal

J Clin Endocrinol Metab

Publication Date

01/1984

Volume

58

Pages

99 - 104

Keywords

Aminoglutethimide, Androstenedione, Breast Neoplasms, Dehydroepiandrosterone, Estradiol, Estrone, Female, Hormones, Humans, Hydrocortisone, Neoplasm Recurrence, Local, Neoplasms, Hormone-Dependent, Prolactin